Skip to menu Skip to content Skip to footer

2024

Journal Article

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Machiels, Jean-Pascal, Tao, Yungan, Licitra, Lisa, Burtness, Barbara, Tahara, Makoto, Rischin, Danny, Alves, Gustavo, Lima, Iane Pinto Figueiredo, Hughes, Brett G M, Pointreau, Yoann, Aksoy, Sercan, Laban, Simon, Greil, Richard, Burian, Martin, Hetnał, Marcin, Delord, Jean-Pierre, Mesía, Ricard, Taberna, Miren, Waldron, John N, Simon, Christian, Grégoire, Vincent, Harrington, Kevin J, Swaby, Ramona F, Zhang, Yayan, Gumuscu, Burak, Bidadi, Behzad, Siu, Lillian L, Hughes, Brett GM, Gao, Bo ... Obara, Grzegorz S (2024). Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. The Lancet Oncology, 25 (5), 572-587. doi: 10.1016/S1470-2045(24)00100-1

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

2024

Journal Article

Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland

Porceddu, Sandro, Negrello, Theresa, Rawson, Neal, Dunn, Nathan, Batstone, Martin, Collins, Michael, Dowthwaite, Sam, Hughes, Brett G. M., Kenny, Liz, Ladwa, Rahul, Panizza, Ben and Cossio, Danica (2024). Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland. Journal of Medical Imaging and Radiation Oncology, 68 (4), 472-480. doi: 10.1111/1754-9485.13643

Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland

2024

Journal Article

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Rischin, Danny, Hughes, Brett G. M., Basset-Séguin, Nicole, Schadendorf, Dirk, Bowyer, Samantha, Trabelsi Messai, Sabiha, Meier, Friedegund, Eigentler, Thomas K, Casado Echarren, Victoria, Stein, Brian, Beylot-Barry, Marie, Dalac, Sophie, Dréno, Brigitte, Migden, Michael R, Hauschild, Axel, Schmults, Chrysalyne D, Lim, Annette M, Yoo, Suk-Young, Paccaly, Anne J, Papachristos, Apostolos, Nguyen, Jenny-Hoa, Okoye, Emmanuel, Seebach, Frank, Booth, Jocelyn, Lowy, Israel, Fury, Matthew G and Guminski, Alexander (2024). High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer, 12 (3) e008325, 1-8. doi: 10.1136/jitc-2023-008325

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

2024

Journal Article

Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme

Alexander, Marliese, Rogers, Jennifer, Parakh, Sagun, Mitchell, Paul, Clay, Timothy D., Kao, Steven, Hughes, Brett G. M., Itchins, Malinda, Kong, Benjamin Y., Pavlakis, Nick, Solomon, Benjamin J. and John, Thomas (2024). Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme. Internal Medicine Journal, 54 (7), 1087-1096. doi: 10.1111/imj.16348

Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme

2024

Journal Article

Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study

McLean, Luke S, Lim, Annette M, Bressel, Mathias, Lee, Jenny, Ladwa, Rahul, Guminski, Alexander D, Hughes, Brett, Bowyer, Samantha, Briscoe, Karen, Harris, Samuel, Kukard, Craig, Zielinski, Rob, Alamgeer, Muhammad, Carlino, Matteo, Mo, Jeremy, Park, John J, Khattak, Muhammad A, Day, Fiona and Rischin, Danny (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia, 220 (2), 80-90. doi: 10.5694/mja2.52199

Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study

2024

Journal Article

Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy

Blake, Claire, Lai, Rainbow, Brown, Teresa, Pelecanos, Anita, Moroney, Laura, Helios, Jennifer, Smith, David, Hughes, Brett G. M., Kenny, Lizbeth, Chua, Benjamin and Bauer, Judith (2024). Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy. Journal of Human Nutrition and Dietetics, 37 (1), 182-192. doi: 10.1111/jhn.13243

Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy

2023

Journal Article

Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629

Bratland, Åse, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, González, Rene, Schachter, Jacob, Arance, Ana M., Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett G. M., Grob, Jean-Jacques, Ramakrishnan, Karthik, Ge, Joy, Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2023). Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629. Dermatology and Therapy, 13 (12), 3165-3180. doi: 10.1007/s13555-023-01059-y

Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629

2023

Journal Article

A tailored approach to horizon scanning for cancer medicines

Soon, Jennifer A., To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A., Athan, Sophy, Brown, Michael P., Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T., Long, Georgina V., Loree, Jonathan M., Markman, Ben, Meniawy, Tarek M., Menzies, Alexander M., Nott, Louise, Pavlakis, Nick, Petrella, Teresa M., Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J. ... IJzerman, Maarten (2023). A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy, 38 100441, 1-8. doi: 10.1016/j.jcpo.2023.100441

A tailored approach to horizon scanning for cancer medicines

2023

Journal Article

Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study

Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo Bernard, Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G. M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Yoo, Suk-Young, Mathias, Melissa, Han, Hyunsil, Seebach, Frank, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2023). Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet Oncology, 24 (11), 1196-1205. doi: 10.1016/S1470-2045(23)00459-X

Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study

2023

Journal Article

Development and validation of txSim: A model of advanced lung cancer treatment in Australia

Ngo, Preston, Karikios, Deme, Goldsbury, David, Wade, Stephen, Lwin, Zarnie, Hughes, Brett G. M., Fong, Kwun M., Canfell, Karen and Weber, Marianne (2023). Development and validation of txSim: A model of advanced lung cancer treatment in Australia. PharmacoEconomics, 41 (11), 1525-1537. doi: 10.1007/s40273-023-01291-6

Development and validation of txSim: A model of advanced lung cancer treatment in Australia

2023

Journal Article

Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment

Jhaveri, Niyati, Ben Cheikh, Bassem, Nikulina, Nadezhda, Ma, Ning, Klymyshyn, Dmytro, DeRosa, James, Mihani, Ritu, Pratapa, Aditya, Kassim, Yasmin, Bommakanti, Sidharth, Shang, Olive, Berry, Shannon, Ihley, Nicholas, McLane, Michael, He, Yan, Zheng, Yi, Monkman, James, Cooper, Caroline, O'Byrne, Ken, Anand, Bhaskar, Prater, Michael, Basu, Subham, Hughes, Brett G. M., Kulasinghe, Arutha and Braubach, Oliver (2023). Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment. GEN Biotechnology, 2 (5), 418-434. doi: 10.1089/genbio.2023.0029

Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment

2023

Journal Article

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Sadeghirad, Habib, Liu, Ning, Monkman, James, Ma, Ning, Cheikh, Bassem Ben, Jhaveri, Niyati, Tan, Chin Wee, Warkiani, Majid Ebrahimi, Adams, Mark N., Nguyen, Quan, Ladwa, Rahul, Braubach, Oliver, O’Byrne, Ken, Davis, Melissa, Hughes, Brett G. M. and Kulasinghe, Arutha (2023). Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy. Frontiers in Immunology, 14 1135489, 1-16. doi: 10.3389/fimmu.2023.1135489

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

2023

Journal Article

LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancer

Alexander, Marliese, Wei, Joe, Parakh, Sagun, John, Thomas, Kao, Steven, Nagrial, Adnan, Bowyer, Samantha, Warburton, Lydia, Moore, Melissa, Hughes, Brett G. M., Clay, Timothy D., Pavlakis, Nick, Solomon, Benjamin J. and Itchins, Malinda (2023). LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancer. JTO Clinical and Research Reports, 4 (4) 100490, 1-13. doi: 10.1016/j.jtocrr.2023.100490

LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancer

2023

Journal Article

Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy

Blake, Claire L., Brown, Teresa E., Pelecanos, Anita, Moroney, Laura B., Helios, Jennifer, Hughes, Brett G. M., Chua, Benjamin and Kenny, Lizbeth M. (2023). Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy. Head and Neck, 45 (2), 417-430. doi: 10.1002/hed.27249

Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy

2023

Journal Article

Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

Taylor, Matthew H., Leboulleux, Sophie, Panaseykin, Yury, Konda, Bhavana, de La Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Park, Young Joo, Romanov, Ilia, Krzyzanowska, Monika K., Garbinsky, Diana, Sherif, Bintu, Pan, Jie Janice, Binder, Terri A., Sauter, Nicholas, Xie, Ran and Brose, Marcia S. (2023). Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Medicine, 12 (4), 4332-4342. doi: 10.1002/cam4.5308

Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

2022

Journal Article

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

Miller, Richard A., Luke, Jason John, Hu, Shenshen, Mahabhashyam, Suresh, Jones, William B., Marron, Thomas, Merchan, Jaime R., Hughes, Brett G. M. and Willingham, Stephen B. (2022). Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for ImmunoTherapy of Cancer, 10 (12) e005802, e005802. doi: 10.1136/jitc-2022-005802

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

2022

Journal Article

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Jiang, Yingying, Shi, Yue, Liu, Yiling, Wang, Zihan, Ma, Yuxin, Shi, Xinhong, Lu, Lin, Wang, Zhitong, Li, Hang, Zhang, Yushu, Liu, Caolu, Zhang, Shaorui, Zhong, Zhihao, Lu, Jianwei, Shi, Meiqi, Shen, Bo, Zhou, Guoren, Yin, Rong, Galetta, Domenico, Grenda, Anna, Romero, Atocha, Hughes, Brett G. M., Chen, Cheng, Wang, Xiaohua and Feng, Jifeng (2022). Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study. Translational Lung Cancer Research, 11 (12), 2521-2538. doi: 10.21037/tlcr-22-857

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

2022

Journal Article

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study

Harrington, Kevin J., Burtness, Barbara, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Lin, Jianxin, Gumuscu, Burak, Swaby, Ramona F. and Rischin, Danny (2022). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 41 (4), 790-802. doi: 10.1200/jco.21.02508

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study

2022

Journal Article

Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma

Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G. and Rischin, Danny (2022). Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. New England Journal of Medicine, 387 (17), 1557-1568. doi: 10.1056/nejmoa2209813

Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma

2022

Journal Article

Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review

Edwards, Anna, Hughes, Brett G M, Brown, Teresa and Bauer, Judith (2022). Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review. Advances in Nutrition, 13 (6), 2433-2444. doi: 10.1093/advances/nmac076

Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review